🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain

RecruitingNAAges 18 Years - anyAllThe First Affiliated Hospital of Zhengzhou Univer…
NCT06747728 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Glioblastoma (GBM) usually grows in a diffuse fashion and infiltrates the surrounding brain. The inability to completely excise the tumor often leads to tumor recurrence within a few months of the initial surgery, which ultimately results in the death of the GBM patient.GBM histologically appears to be a tumor of vascular origin characterized by necrosis and microvascular proliferation, and neoangiogenesis is a key factor in the growth and poor prognosis of GBM. Bevacizumab can inhibit the biological effects of VEGF, including the permeability and proliferation of blood vessels, as well as the migration and survival of endothelial cells, so as to inhibit tumor angiogenesis, growth and metastasis. The aim of this study is to evaluate the efficacy and safety of bevacizumab in the preoperative adjuvant treatment of patients with new-onset high-grade gliomas.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 years. * Male or female. * Imaging diagnosis of high-grade glioma. * KPS score ≥60. Exclusion Criteria: * Prior treatment with anti-angiogenic targeted drugs; * Comorbid serious cardiac, pulmonary, hepatic, or renal disease; * History of an arterial/venous thrombotic event within 6 months prior to screening; * Combination of infectious diseases such as tuberculosis and viral hepatitis; * Comorbid infectious diseases such as tuberculosis, viral hepatitis, uncontrolled high blood pressure, bleeding disorders, and long-standing unhealed wounds or incompletely healed fractures; * Patients with a history of psychotropic substance abuse that cannot be stopped or patients with mental disorders; * Abnormal coagulation function, with bleeding tendency * Patients who, in the opinion of the investigator, are not suitable for inclusion in the study (e.g., pregnant and lactating women).
💊

What it tests

  • Bevacizumab
📍

Where

1 site
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy